Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 86132
1. Kenawy S, Hegazy R, Hassan A, El-Shenawy S, Gomaa N, Zaki H, Attia A: Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin. PLoS One; 2017;12(8):e0183565
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin.
  • Age-related dementia is one of the most devastating disorders affecting the elderly.
  • Recently, emerging data suggest that impaired insulin signaling is the major contributor in the development of Alzheimer's dementia (AD), which is the most common type of senile dementia.
  • Reversing of these harmful effects by the use of insulin-sensitizing drugs like Met and Saxa suggests their involvement in alleviation insulin resistance as the underlying pathology of AD and hence their potential use as anti-dementia drugs.
  • [MeSH-major] Adamantane / analogs & derivatives. Aging / pathology. Dementia / chemically induced. Dipeptides / toxicity. Galactose / toxicity. Hypoglycemic Agents / therapeutic use. Insulin Resistance. Metformin / therapeutic use

  • MedlinePlus Health Information. consumer health - Dementia.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. METFORMIN HYDROCHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gerontologist. 2016 Apr;56 Suppl 2:S167-77 [26994258.001]
  • [Cites] Oxid Med Cell Longev. 2014;2014:320513 [24669284.001]
  • [Cites] Nat Med. 2004 Jul;10(7):719-26 [15195085.001]
  • [Cites] J Lab Clin Med. 1963 May;61:882-8 [13967893.001]
  • [Cites] J Alzheimers Dis. 2016;51(4):1197-208 [26967226.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2004 Mar;286(3):R431-44 [14761864.001]
  • [Cites] J Neurogenet. 2015;29(2-3):50-8 [26119401.001]
  • [Cites] Cold Spring Harb Perspect Med. 2016 Mar 01;6(3):a025932 [26931809.001]
  • [Cites] Neurobiol Learn Mem. 2011 Oct;96(3):432-42 [21907815.001]
  • [Cites] Mol Psychiatry. 2003 Sep;8(9):786-96 [12931206.001]
  • [Cites] Mol Neurobiol. 2017 Jan;54(1):255-271 [26738855.001]
  • [Cites] J Neurol Sci. 2006 Jun 15;245(1-2):21-33 [16631207.001]
  • [Cites] Mol Psychiatry. 2010 Nov;15(11):1046-52 [20966918.001]
  • [Cites] Vascul Pharmacol. 2016 Jan;76:62-71 [26455387.001]
  • [Cites] Neuropharmacology. 2016 Feb;101:123-36 [26211973.001]
  • [Cites] J Diabetes Complications. 2016 May-Jun;30(4):746-52 [26796432.001]
  • [Cites] J Ethnopharmacol. 2016 Feb 17;179:162-9 [26721223.001]
  • [Cites] Kidney Res Clin Pract. 2016 Jun;35(2):69-77 [27366660.001]
  • [Cites] Gerontologist. 1997 Apr;37(2):150-6 [9127971.001]
  • [Cites] CNS Neurol Disord Drug Targets. 2016;15(3):329-36 [26831258.001]
  • [Cites] Pharmacol Biochem Behav. 2012 Jun;101(4):564-74 [22425595.001]
  • [Cites] J Alzheimers Dis. 2005 Dec;8(3):247-68 [16340083.001]
  • [Cites] Curr Top Med Chem. 2016;16(5):485-92 [26268336.001]
  • [Cites] Behav Brain Res. 2011 Jun 20;220(1):30-41 [21262264.001]
  • [Cites] Expert Rev Neurother. 2010 May;10(5):683-91 [20420489.001]
  • [Cites] J Neurochem. 2004 Jun;89(6):1313-7 [15189333.001]
  • [Cites] Neuropharmacology. 2013 Sep;72:291-300 [23603201.001]
  • [Cites] Expert Opin Investig Drugs. 2015 Mar;24(3):393-9 [25586103.001]
  • [Cites] Curr Atheroscler Rep. 2016 Apr;18(4):16 [26888066.001]
  • [Cites] J Neuroimmunol. 1999 Jan 1;93(1-2):182-93 [10378882.001]
  • [Cites] Mol Neurobiol. 2016 Apr;53(3):1741-1752 [25744568.001]
  • [Cites] Anal Biochem. 1989 Aug 1;180(2):248-52 [2573290.001]
  • [Cites] Biotherapy. 1991;3(2):127-33 [2054253.001]
  • [Cites] Brain Res Bull. 2017 Jul;133:88-96 [27316747.001]
  • [Cites] Alzheimers Dement. 2016 Jun;12(6):719-32 [27179961.001]
  • [Cites] J Vis Exp. 2011 Jul 20;(53):null [21808223.001]
  • [Cites] Arch Neurol. 2011 Jan;68(1):51-7 [20837822.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] Cell Cycle. 2014;13(6):898-909 [24552807.001]
  • [Cites] J Pharm Sci. 1983 May;72(5):465-92 [6345750.001]
  • [Cites] J Nutr Health Aging. 2016 Apr;20(4):439-45 [26999245.001]
  • [Cites] Eur J Pharmacol. 2011 Jun 25;660(2-3):363-7 [21497160.001]
  • [Cites] Rev Neurosci. 2011;22(3):285-94 [21568789.001]
  • [Cites] J Cell Sci. 2001 Apr;114(Pt 8):1429-30 [11282018.001]
  • [Cites] Ann N Y Acad Sci. 2008 Apr;1126:147-51 [18448809.001]
  • [Cites] Lancet. 1994 Sep 17;344(8925):769-72 [7916070.001]
  • [Cites] J Alzheimers Dis. 2016;51(2):515-23 [26890783.001]
  • [Cites] PLoS One. 2015 Dec 02;10(12):e0143814 [26629991.001]
  • [Cites] Biomed Rep. 2016 May;4(5):519-522 [27123241.001]
  • [Cites] Mol Neurobiol. 2013 Dec;48(3):556-70 [23546742.001]
  • (PMID = 28832656.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Dipeptides; 0 / Hemoglobin A, Glycosylated; 0 / Hypoglycemic Agents; 0 / Nerve Tissue Proteins; 9100L32L2N / Metformin; 9GB927LAJW / saxagliptin; PJY633525U / Adamantane; X2RN3Q8DNE / Galactose
  •  go-up   go-down


2. Moyle W, El Saifi N, Draper B, Jones C, Beattie E, Shum D, Thalib L, Mervin C, O Dwyer S: Pharmacotherapy of Persons with Dementia in Long-Term Care in Australia: A Descriptive Audit of Central Nervous System Medications. Curr Drug Saf; 2017 Feb 09;
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacotherapy of Persons with Dementia in Long-Term Care in Australia: A Descriptive Audit of Central Nervous System Medications.
  • BACKGROUND: Neuropsychiatric symptoms of dementia are often treated through the prescription of one or more psychotropic medications.
  • OBJECTIVES: This study sought to describe the pattern of central nervous system medication usage in older adults with dementia living in long-term care; assess the appropriateness of prescribing against Beers criteria; and detect potential drug interactions from co-administered medications.
  • METHODS: A retrospective descriptive audit of the medical records of n=415 residents, aged >60 years with a diagnosis of dementia, from 28 long-term care facilities in Queensland, Australia.
  • CONCLUSIONS: This medication audit raises concerns that prescription of medications may still be the first resort to treat behavioural and psychological symptoms of dementia.
  • There is a need for effective and sustainable person-centred interventions that address barriers for appropriate prescribing practice, and involve the collaboration of all healthcare professionals to optimise prescribing and improve the quality use of medicines in older people with dementia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
  • [Cites] J Am Geriatr Soc. 2015 Nov;63(11):2227-46 [26446832.001]
  • [Cites] Int J Older People Nurs. 2013 Mar;8(1):61-70 [22340956.001]
  • [Cites] Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):283-90 [17132974.001]
  • [Cites] Age Ageing. 2010 Jul;39(4):488-94 [20511245.001]
  • [Cites] Age Ageing. 2015 Jul;44(4):704-8 [25758409.001]
  • [Cites] BMJ Open. 2015 Aug 12;5(8):e009097 [26270953.001]
  • [Cites] Nurs Times. 2014 Jun 4-10;110(23 ):12-5 [25016733.001]
  • [Cites] Int Psychogeriatr. 2006 Mar;18(1):111-20 [16466591.001]
  • [Cites] Age Ageing. 2011 Mar;40(2):150-62 [21262782.001]
  • [Cites] Health Technol Assess. 2014 Jun;18(39):1-226, v-vi [24947468.001]
  • [Cites] J Am Geriatr Soc. 2012 Mar;60(3):420-9 [22329464.001]
  • [Cites] Intern Med J. 2007 Jun;37(6):402-5 [17535384.001]
  • [Cites] Can J Psychiatry. 2014 Dec;59(12):618-23 [25702360.001]
  • [Cites] Clin Interv Aging. 2014 Aug 16;9:1363-73 [25170260.001]
  • [Cites] Aust N Z J Psychiatry. 2005 Nov-Dec;39(11-12):1030-5 [16343306.001]
  • [Cites] J Clin Pharm Ther. 2011 Feb;36(1):33-44 [21198718.001]
  • [Cites] Geriatr Nurs. 1994 May-Jun;15(3):142-6 [7926933.001]
  • [Cites] Int J Geriatr Psychiatry. 2008 May;23(5):490-6 [17944007.001]
  • [Cites] Int J Geriatr Psychiatry. 2014 Oct;29(10):1049-61 [24648059.001]
  • [Cites] Aging Ment Health. 2010 Nov;14(8):905-16 [20635236.001]
  • [Cites] Int J Geriatr Psychiatry. 2009 Mar;24(3):226-31 [18666309.001]
  • [Cites] Aust New Zealand Health Policy. 2009 Aug 11;6:18 [19671158.001]
  • (PMID = 28183240.001).
  • [ISSN] 2212-3911
  • [Journal-full-title] Current drug safety
  • [ISO-abbreviation] Curr Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United Arab Emirates
  • [Keywords] NOTNLM ; Dementia / Drug interactions / Geriatrics / Long-term care / Medication / Prescribing
  •  go-up   go-down


3. Lowe VJ, Lundt E, Knopman D, Senjem ML, Gunter JL, Schwarz CG, Kemp BJ, Jack CR Jr, Petersen RC: Comparison of [<sup>18</sup>F]Flutemetamol and [<sup>11</sup>C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals. Neuroimage Clin; 2017;16:295-302

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of [<sup>18</sup>F]Flutemetamol and [<sup>11</sup>C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals.
  • METHODS: Structural MRI, FMT PET and PiB PET were each performed in 30 young cognitively normal (yCN), 31 elderly cognitively normal (eCN) and 21 Alzheimer's disease dementia (AD) participants.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2009 Aug;50(8):1251-9 [19617318.001]
  • [Cites] Alzheimers Dement. 2015 Jan;11(1):1-15.e1-4 [25443857.001]
  • [Cites] Lancet Neurol. 2011 May;10 (5):424-35 [21481640.001]
  • [Cites] Neuroimage Clin. 2015 Oct 14;9:592-8 [26640770.001]
  • [Cites] Acta Neuropathol. 2012 Dec;124(6):823-31 [22864813.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):983-9 [22398958.001]
  • [Cites] Ann Neurol. 2007 Sep;62(3):229-34 [17683091.001]
  • [Cites] Neurology. 2014 Jun 3;82(22):1959-67 [24793183.001]
  • [Cites] Neuroimage. 2017 Jan 1;144(Pt A):113-127 [27577718.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):290-300 [24085503.001]
  • [Cites] J Nucl Med. 1999 Dec;40(12 ):2053-65 [10616886.001]
  • [Cites] Arch Neurol. 2010 Nov;67(11):1379-85 [21060015.001]
  • [Cites] Alzheimers Dement. 2011 May;7(3):263-9 [21514250.001]
  • [Cites] Brain. 2008 Jun;131(Pt 6):1630-45 [18339640.001]
  • [Cites] J Cereb Blood Flow Metab. 1992 Jul;12 (4):571-83 [1618936.001]
  • [Cites] Neurobiol Aging. 2012 May;33(5):878-85 [20961664.001]
  • [Cites] Lancet Neurol. 2012 Aug;11(8):669-78 [22749065.001]
  • [Cites] J Nucl Med. 2009 Jun;50(6):878-86 [19443597.001]
  • [Cites] Neuroepidemiology. 2008;30(1):58-69 [18259084.001]
  • [Cites] J Nucl Med. 2015 Apr;56(4):567-74 [25745095.001]
  • [Cites] Ann Neurol. 2004 Mar;55(3):306-19 [14991808.001]
  • [Cites] Biometrics. 1988 Sep;44(3):837-45 [3203132.001]
  • [Cites] J Cereb Blood Flow Metab. 2005 Nov;25(11):1528-47 [15944649.001]
  • [Cites] Stat Med. 2006 Feb 28;25(4):559-73 [16217835.001]
  • [Cites] J Nucl Med. 2014 Oct;55(10 ):1623-8 [25146124.001]
  • [Cites] Alzheimers Dement. 2011 May;7(3):270-9 [21514249.001]
  • [Cites] Neuroimage. 2005 Jul 1;26(3):839-51 [15955494.001]
  • [Cites] Brain Imaging Behav. 2009 Sep;3(3):246-61 [22005989.001]
  • [Cites] J Nucl Med. 2015 Apr;56(4):560-6 [25745091.001]
  • [Cites] Stat Med. 2006 Feb 28;25(4):591-602 [16143965.001]
  • [Cites] Alzheimers Dement. 2017 Mar;13(3):205-216 [27697430.001]
  • [Cites] Brain. 2009 May;132(Pt 5):1355-65 [19339253.001]
  • (PMID = 28856092.001).
  • [ISSN] 2213-1582
  • [Journal-full-title] NeuroImage. Clinical
  • [ISO-abbreviation] Neuroimage Clin
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


Advertisement
4. Karlsson S, Rahm Hallberg I, Midlöv P, Fagerström C: Trends in treatment with antipsychotic medication in relation to national directives, in people with dementia - a review of the Swedish context. BMC Psychiatry; 2017 Jul 14;17(1):251
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in treatment with antipsychotic medication in relation to national directives, in people with dementia - a review of the Swedish context.
  • BACKGROUND: The aim of this study was to explore trends in treatment with antipsychotic medication in Swedish dementia care in nursing homes as reported in the most recent empirical studies on the topic, and to relate these trends to directives from the national authorities.
  • The scoping review showed that treatment with antipsychotic drugs varied between 6% and 38%, and was higher in younger older persons and in those with moderate cognitive impairment and living in nursing homes for people with dementia.
  • CONCLUSIONS: Directives from the authorities in Sweden may have had an impact on treatment with antipsychotic medication for people with dementia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Health Serv Res. 2012 Oct;47(5):1791-813 [22946859.001]
  • [Cites] J Am Geriatr Soc. 2002 Jun;50(6):995-1000 [12110057.001]
  • [Cites] Int Psychogeriatr. 2009 Oct;21(5):941-8 [19586566.001]
  • [Cites] Arch Intern Med. 2007 Apr 9;167(7):676-83 [17420426.001]
  • [Cites] Int Psychogeriatr. 2010 Nov;22(7):1154-60 [20478102.001]
  • [Cites] Am J Geriatr Psychiatry. 2015 Dec;23(12):1259-69 [26525997.001]
  • [Cites] Lancet. 2005 Dec 17;366(9503):2112-7 [16360788.001]
  • [Cites] Int J Surg. 2010;8(5):336-41 [20171303.001]
  • [Cites] Dement Geriatr Cogn Disord. 2008;26(5):458-66 [18984956.001]
  • [Cites] Int J Geriatr Psychiatry. 2013 Jul;28(7):700-9 [22887592.001]
  • [Cites] BMC Public Health. 2012 Jan 23;12:68 [22269343.001]
  • [Cites] Ann Pharmacother. 2012 Jul-Aug;46(7-8):917-28 [22811347.001]
  • [Cites] Clin Drug Investig. 2010;30(5):289-300 [20384385.001]
  • [Cites] Health Serv Res. 2011 Dec;46(6pt1):1698-719 [21790590.001]
  • [Cites] Health Technol Assess. 2014 Jun;18(39):1-226, v-vi [24947468.001]
  • [Cites] Dement Geriatr Cogn Disord. 2004;17(1-2):78-90 [14566100.001]
  • [Cites] Aust N Z J Psychiatry. 2013 Jan;47(1):74-87 [23144164.001]
  • [Cites] Eur Neuropsychopharmacol. 2014 Jan;24(1):95-104 [24126116.001]
  • [Cites] Aging Clin Exp Res. 2004 Apr;16(2):158-68 [15195992.001]
  • [Cites] Int J Geriatr Psychiatry. 2009 Dec;24(12):1386-95 [19370714.001]
  • [Cites] BMC Pharmacol Toxicol. 2013 Nov 07;14:56 [24196341.001]
  • [Cites] Int J Geriatr Psychiatry. 2008 Mar;23(3):289-94 [17645282.001]
  • [Cites] Health Econ. 2012 Aug;21(8):977-93 [21882284.001]
  • [Cites] Int J Geriatr Psychiatry. 2001 Sep;16(9):900-6 [11571771.001]
  • [Cites] Int Psychogeriatr. 2011 Dec;23(10):1616-22 [21902862.001]
  • [Cites] Int Psychogeriatr. 2006 Dec;18(4):713-26 [16879762.001]
  • [Cites] JAMA. 1994 Feb 2;271(5):358-62 [8283585.001]
  • [Cites] Eur J Clin Pharmacol. 2016 Aug;72 (8):987-94 [27071994.001]
  • [Cites] Alzheimers Dement. 2012 Sep;8(5):453-7 [22285636.001]
  • [Cites] Health Serv Res. 2009 Apr;44(2 Pt 1):379-98 [19178586.001]
  • [Cites] BMC Pharmacol Toxicol. 2013 Feb 08;14:10 [23391323.001]
  • [Cites] Arch Gen Psychiatry. 2011 Feb;68(2):190-7 [21300946.001]
  • [Cites] Acta Psychiatr Scand. 2015 Jul;132(1):20-8 [25532774.001]
  • [Cites] Am J Alzheimers Dis Other Demen. 2011 Feb;26(1):10-28 [21282274.001]
  • [Cites] Dement Geriatr Cogn Disord. 2013;35(5-6):239-48 [23485654.001]
  • [Cites] J Am Med Dir Assoc. 2014;15(11):812-8 [25129474.001]
  • [Cites] PLoS Med. 2008 Apr 1;5(4):e76 [18384230.001]
  • [Cites] Int Psychogeriatr. 2013 Sep;25(9):1415-23 [23782794.001]
  • [Cites] Int J Geriatr Psychiatry. 2014 Mar;29(3):263-71 [23846797.001]
  • [Cites] JAMA. 2005 Feb 2;293(5):596-608 [15687315.001]
  • (PMID = 28705243.001).
  • [ISSN] 1471-244X
  • [Journal-full-title] BMC psychiatry
  • [ISO-abbreviation] BMC Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Antipsychotic medication / Dementia / Directive / Drug utilization
  •  go-up   go-down


5. Endres D, Vry MS, Dykierek P, Riering AN, Lüngen E, Stich O, Dersch R, Venhoff N, Erny D, Mader I, Meyer PT, Tebartz van Elst L: Plasmapheresis Responsive Rapid Onset Dementia with Predominantly Frontal Dysfunction in the Context of Hashimoto's Encephalopathy. Front Psychiatry; 2017;8:212

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmapheresis Responsive Rapid Onset Dementia with Predominantly Frontal Dysfunction in the Context of Hashimoto's Encephalopathy.
  • Background: Hashimoto's encephalopathy (HE) is a rare immunological neuropsychiatric disorder characterized by increased antithyroid antibodies and mixed neurological and psychiatric symptoms.
  • HE has been previously discussed as a differential diagnosis for rapid progressive dementia.
  • However, most of these patients suffered from additional neurological symptoms, like ataxia or seizures.
  • Case presentation: Here, we present the case of a 59-year-old female patient suffering rapid onset dementia with salient frontal executive dysfunction.
  • She developed rapid onset symptoms, including apathy, verbal depletion up to a stuporous state, severe working memory deficits, evidence of primitive reflexes, disturbed Luria's three-step test, and micturition disorder.
  • Due to the organic alterations, including increased antithyroid antibodies, HE was suspected.
  • Conclusion: This case report reveals that (1) HE can mimic rapid onset dementia with predominantly frontal dysfunction;.
  • (2) this syndrome can be successfully treated in the context of HE; and (3) plasmapheresis can be effective in such a disease constellation.
  • The detection of the immunological causes of rapid onset dementia and other psychiatric syndromes is important because it opens opportunities for new, innovative immunosuppressive treatment options.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Autoimmun Rev. 2016 Dec;15(12 ):1129-1133 [27639840.001]
  • [Cites] J Neurol. 2008 Dec;255 Suppl 6:36-42 [19300958.001]
  • [Cites] Case Rep Psychiatry. 2016;2016:4168050 [27688922.001]
  • [Cites] Nervenarzt. 2014 Apr;85(4):485-98; quiz 499-501 [24668402.001]
  • [Cites] Front Psychiatry. 2017 Apr 21;8:64 [28484400.001]
  • [Cites] J Neuroimmunol. 2007 Dec;192(1-2):13-20 [17963848.001]
  • [Cites] Eur J Neurol. 2004 Oct;11(10):711-3 [15469458.001]
  • [Cites] BMC Psychiatry. 2016 Jun 06;16:184 [27268005.001]
  • [Cites] Front Hum Neurosci. 2017 Feb 20;11:66 [28265243.001]
  • [Cites] Arch Neurol. 2006 Feb;63(2):197-202 [16476807.001]
  • [Cites] J Clin Apher. 2015 Jun;30(3):188-92 [25116126.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Nov;73(5):601-2 [12397166.001]
  • [Cites] J Neurol Sci. 2004 Feb 15;217(2):165-8 [14706219.001]
  • [Cites] Nervenarzt. 2013 Apr;84(4):455-60 [23443876.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):489-99 [11836274.001]
  • [Cites] Cureus. 2016 Jul 05;8(7):e672 [27672526.001]
  • [Cites] J Family Med Prim Care. 2014 Jul;3(3):284-6 [25374873.001]
  • [Cites] Epilepsy Behav. 2011 Oct;22(2):231-9 [21784710.001]
  • [Cites] Neurology. 2003 Feb 25;60(4):712-4 [12601119.001]
  • [Cites] Hum Brain Mapp. 2008 Jan;29(1):36-45 [17290369.001]
  • [Cites] Fluids Barriers CNS. 2015 Dec 13;12:27 [26652013.001]
  • [Cites] Psychosomatics. 2013 Nov-Dec;54(6):599-603 [23453127.001]
  • [Cites] J Neurol Sci. 2011 Mar 15;302(1-2):114-7 [21196016.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):172-6 [10071095.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 2017 Fall;29(4):365-374 [28449636.001]
  • [Cites] Arch Neurol. 2003 Feb;60(2):164-71 [12580699.001]
  • [Cites] Neurology. 2011 Jan 18;76(3):294-300 [21242498.001]
  • [Cites] Int J Psychiatry Clin Pract. 2016 Sep;20(3):157-64 [27181256.001]
  • [Cites] Lancet Neurol. 2016 Apr;15(4):391-404 [26906964.001]
  • (PMID = 29123489.001).
  • [ISSN] 1664-0640
  • [Journal-full-title] Frontiers in psychiatry
  • [ISO-abbreviation] Front Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Hashimoto’s encephalopathy / SREAT / frontotemporal dementia / plasmapheresis / thyroid
  •  go-up   go-down


6. Hedna K, Andersson Sundell K, Hamidi A, Skoog I, Gustavsson S, Waern M: Antidepressants and suicidal behaviour in late life: a prospective population-based study of use patterns in new users aged 75 and above. Eur J Clin Pharmacol; 2017 Nov 04;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Decreased risk of attempt was observed among those with concomitant use of anti-dementia drugs (0.40, 0.27 to 0.59).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29103090.001).
  • [ISSN] 1432-1041
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Aged / Antidepressants / Cohort study / Pharmacoepidemiology / Suicide
  •  go-up   go-down


7. Hewer W, Thomas C: [Treatment with psychotropic agents in patients with dementia and delirium : Gap between guideline recommendations and treatment practice]. Z Gerontol Geriatr; 2017 Feb;50(2):106-114
MedlinePlus Health Information. consumer health - Dementia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment with psychotropic agents in patients with dementia and delirium : Gap between guideline recommendations and treatment practice].
  • [Transliterated title] Psychopharmakotherapie bei Demenz und Delir : Im Spannungsfeld zwischen Leitlinienempfehlungen und Versorgungspraxis.
  • BACKGROUND AND OBJECTIVES: Psychiatric symptoms in dementia and delirium are associated with a substantially reduced quality of life of patients and their families and often challenging for professionals.
  • MATERIAL AND METHODS: Narrative review with special reference to the German dementia guideline from 2016 and recently published practice guidelines for delirium in old age in German and English language.
  • RESULTS: The indications for use of psychotropic agents, especially antipsychotics, are defined narrowly in the German dementia guideline.
  • Comparable to the German dementia guideline they recommend general medical interventions and nonpharmacological treatment as first line measures and the use of psychotropic agents only under certain conditions.
  • CONCLUSION: The guidelines discussed here advocate well-founded a cautious prescription of psychotropic agents in patients with dementia and delirium.
  • Most notably, however, epidemiological data disclose an unacceptable rate of hazardous overtreatment with psychotropic agents, especially in long-term care of persons with dementia.
  • [MeSH-major] Delirium / drug therapy. Dementia / drug therapy. Drug Monitoring / standards. Geriatrics / standards. Practice Guidelines as Topic. Psychotropic Drugs / therapeutic use

  • MedlinePlus Health Information. consumer health - Delirium.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Psychiatry. 2016 May 1;173(5):543-6 [27133416.001]
  • [Cites] Int J Geriatr Psychiatry. 2014 Mar;29(3):253-62 [23801358.001]
  • [Cites] Z Gerontol Geriatr. 2016 Jan;49(1):52-8 [25801513.001]
  • [Cites] Int Psychogeriatr. 2013 Dec;25(12):2067-75 [23962713.001]
  • [Cites] Crit Care Med. 2013 Jan;41(1):263-306 [23269131.001]
  • [Cites] Lancet. 2014 Mar 8;383(9920):911-22 [23992774.001]
  • [Cites] Int J Clin Pharmacol Ther. 2016 Nov;54(11):835-840 [27487368.001]
  • [Cites] JAMA. 2005 Oct 19;294(15):1934-43 [16234500.001]
  • [Cites] J Am Coll Surg. 2015 Feb;220(2):136-48.e1 [25535170.001]
  • [Cites] J Am Med Dir Assoc. 2015 Aug 1;16(8):697-701 [25933727.001]
  • [Cites] Palliat Support Care. 2011 Dec;9(4):351-7 [22104410.001]
  • [Cites] Z Gerontol Geriatr. 2015 Jun;48(4):305-11 [25962363.001]
  • [Cites] Int Psychogeriatr. 2013 Apr;25(4):635-43 [23253513.001]
  • [Cites] Br J Psychiatry. 2014 Dec;205(6):478-85 [25359923.001]
  • [Cites] Lancet Psychiatry. 2014 Sep 1;1(4):312-315 [25285270.001]
  • [Cites] N Engl J Med. 2012 Oct 18;367(16):1497-507 [23075176.001]
  • [Cites] JAMA Psychiatry. 2015 May;72 (5):438-45 [25786075.001]
  • [Cites] Drugs Real World Outcomes. 2016 May 13;3(2):175-182 [27398296.001]
  • [Cites] Br J Psychiatry. 2009 Mar;194(3):212-9 [19252147.001]
  • [Cites] Eur Neuropsychopharmacol. 2015 Dec;25(12 ):2333-8 [26476703.001]
  • [Cites] Int Psychogeriatr. 2015 Nov;27(11):1849-59 [26062126.001]
  • [Cites] Nervenarzt. 2010 May;81(5):613-28; quiz 629-30 [20454878.001]
  • [Cites] Pharmacopsychiatry. 2012 Jul;45(5):182-8 [22430201.001]
  • [Cites] J Psychosom Res. 2014 Sep;77(3):240-1 [25149034.001]
  • [Cites] J Am Geriatr Soc. 2016 Apr;64(4):705-14 [27004732.001]
  • [Cites] Z Gerontol Geriatr. 2015 Jun;48(4):312-7 [25957245.001]
  • [Cites] Nervenarzt. 2016 May;87(5):534-42 [26628044.001]
  • [Cites] Pharmacotherapy. 2015 Aug;35(8):731-9 [26238778.001]
  • (PMID = 28124100.001).
  • [ISSN] 1435-1269
  • [Journal-full-title] Zeitschrift fur Gerontologie und Geriatrie
  • [ISO-abbreviation] Z Gerontol Geriatr
  • [Language] ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Psychotropic Drugs
  • [Keywords] NOTNLM ; Administration and dosage / Drug monitoring / Evidence-based medicine / Nonpharmacological treatment
  •  go-up   go-down


8. Cederholm T: Fish consumption and omega-3 fatty acid supplementation for prevention or treatment of cognitive decline, dementia or Alzheimer's disease in older adults - any news? Curr Opin Clin Nutr Metab Care; 2017 Mar;20(2):104-109
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fish consumption and omega-3 fatty acid supplementation for prevention or treatment of cognitive decline, dementia or Alzheimer's disease in older adults - any news?
  • PURPOSE OF REVIEW: Twenty years of research indicates that fish and n-3 fatty acids (FAs), for example docosahexaenoic acid, may attenuate cognitive decline including Alzheimer's disease in older people.
  • Recalculations from a report in Alzheimer's disease patients indicated a dose-response pattern between increments of serum n-3 FAs and cognitive improvement.
  • Still, a Cochrane review (using three randomized control trials) concluded that n-3 FAs cannot provide any 6-month benefit in patients with mild/moderate Alzheimer's disease.
  • SUMMARY: The accumulated knowledge indicates that healthy populations may have preventive benefits from fish and docosahexaenoic acid intake, like older adults with memory complaints/mild cognitive impairment, and maybe subgroups of patients with mild/moderate Alzheimer's disease may also show such benefits.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27977429.001).
  • [ISSN] 1473-6519
  • [Journal-full-title] Current opinion in clinical nutrition and metabolic care
  • [ISO-abbreviation] Curr Opin Clin Nutr Metab Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Tai SY, Chien CY, Chang YH, Yang YH: Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study. Neurotherapeutics; 2017 Jul;14(3):784-791

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study.
  • We examined the potential association between the use of cilostazol, an antiplatelet agent and cyclic adenosine monophosphate phosphodiesterase 3 inhibitor, and the risk of dementia in an Asian population.
  • Patients initiating cilostazol therapy between 1 January 2004 and 31 December 2009 without a prior history of dementia were identified from Taiwan's National Health Insurance database.
  • The outcome of interest was all-cause dementia (ICD-9-CM codes 290.0, 290.4, 294.1, 331.0).
  • Cox regression models were used to estimate the hazard ratio (HR) of dementia.
  • A total of 9148 participants 40 years of age or older and free of dementia at baseline were analyzed.
  • Patients using cilostazol (n = 2287) had a significantly decreased risk of incident dementia compared with patients not using the drug [n = 6861; adjusted HR (aHR) 0.75; 95% confidence interval (CI) 0.61-0.92].
  • Notably, cilostazol use was found to have a dose-dependent association with reduced rate of dementia emergence (p for trend = 0.001).
  • Subgroup analysis identified a decline of dementia in cilostazol users with diagnosed ischemic heart disease (aHR 0.44, 95% CI 0.24-0.83) and cerebral vascular disease (aHR 0.34, 95% CI 0.21-0.54).
  • These observations suggest that cilostazol use may reduce the risk to develop dementia, and a high cumulative dose further decreases the risk of dementia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Stroke Cerebrovasc Dis. 2001 Mar-Apr;10(2):63-9 [17903802.001]
  • [Cites] Brain Res. 2006 Apr 12;1082(1):182-91 [16516167.001]
  • [Cites] Am Heart J. 2016 Mar;173:134-42 [26920606.001]
  • [Cites] Psychogeriatrics. 2013 Sep;13(3):164-9 [25707423.001]
  • [Cites] J Stroke Cerebrovasc Dis. 2016 May;25(5):1081-9 [26856461.001]
  • [Cites] Curr Pharm Des. 2015;21(3):317-31 [25159073.001]
  • [Cites] Brain Res. 2007 Dec 14;1185:246-55 [17936728.001]
  • [Cites] Vasc Health Risk Manag. 2008;4(6):1197-203 [19337533.001]
  • [Cites] J Neurosci. 2005 Jul 20;25(29):6887-97 [16033898.001]
  • [Cites] Eur J Epidemiol. 2010 Apr;25(4):245-51 [20358262.001]
  • [Cites] Curr Pharm Des. 2006;12(5):565-73 [16472148.001]
  • [Cites] Am J Geriatr Psychiatry. 2009 Apr;17(4):353-4 [19307864.001]
  • [Cites] Br J Clin Pharmacol. 2011 Oct;72(4):634-46 [21649691.001]
  • [Cites] Alzheimers Dement. 2007 Jul;3(3):186-91 [19595937.001]
  • [Cites] J Alzheimers Dis. 2009;16(4):859-64 [19387118.001]
  • [Cites] Stroke. 2012 Feb;43(2):499-506 [22033992.001]
  • [Cites] Alzheimer Dis Assoc Disord. 2004 Oct-Dec;18(4):208-13 [15592132.001]
  • [Cites] Biochem Biophys Res Commun. 2011 May 20;408(4):602-8 [21530492.001]
  • [Cites] Geriatr Gerontol Int. 2013 Jan;13(1):90-7 [22672107.001]
  • [Cites] Cochrane Database Syst Rev. 2006 Jul 19;(3):CD006104 [16856114.001]
  • [Cites] Stroke. 2006 Jun;37(6):1539-45 [16645134.001]
  • [Cites] Stroke. 1989 May;20(5):668-73 [2718208.001]
  • [Cites] PLoS One. 2014 Feb 26;9(2):e89516 [24586841.001]
  • [Cites] Prescrire Int. 2012 Jun;21(128):150 [22822592.001]
  • [Cites] Lancet Neurol. 2010 Oct;9(10):959-68 [20833591.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2016 Jan;43(1):29-33 [26414108.001]
  • (PMID = 28194663.001).
  • [ISSN] 1878-7479
  • [Journal-full-title] Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
  • [ISO-abbreviation] Neurotherapeutics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Dementia / cilostazol / cohort studies
  •  go-up   go-down


10. Orkaby AR, Cho K, Cormack J, Gagnon DR, Driver JA: Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes. Neurology; 2017 Oct 31;89(18):1877-1885
Hazardous Substances Data Bank. METFORMIN HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes.
  • OBJECTIVE: To determine whether metformin is associated with a lower incidence of dementia than sulfonylureas.
  • METHODS: This was a retrospective cohort study of US veterans ≥65 years of age with type 2 diabetes who were new users of metformin or a sulfonylurea and had no dementia.
  • Cox proportional hazards models estimated the hazard ratio (HR) of incident dementia.
  • Over an average follow-up of 5 years, 4,906 cases of dementia were diagnosed.
  • Crude hazard ratio [HR] for any dementia in metformin vs sulfonylurea users was 0.67 (95% confidence interval [CI] 0.61-0.73) and 0.78 (95% CI 0.72-0.83) for those <75 years of age and ≥75 years of age, respectively.
  • A lower risk of dementia was also seen in the subset of younger veterans who had HbA1C values ≥7% (HR 0.76; 95% CI 0.63-0.91), had good renal function (HR 0.86; 95% CI 0.76-0.97), and were white (HR 0.87; 95% CI 0.77-0.99).
  • CONCLUSIONS: After accounting for confounding by indication, metformin was associated with a lower risk of subsequent dementia than sulfonylurea use in veterans <75 years of age.
  • Further work is needed to identify which patients may benefit from metformin for the prevention of dementia.
  • [MeSH-major] Dementia / chemically induced. Dementia / epidemiology. Diabetes Mellitus, Type 2 / drug therapy. Hypoglycemic Agents / adverse effects. Metformin / adverse effects. Sulfonylurea Compounds / adverse effects. Veterans

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Dementia.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 American Academy of Neurology.
  • [Cites] Diabetes Care. 2016 Feb;39(2):300-7 [26681727.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21830-5 [21098287.001]
  • [Cites] Am J Epidemiol. 2003 Nov 1;158(9):915-20 [14585769.001]
  • [Cites] Ann Intern Med. 2016 Jun 7;164(11):740-51 [27088241.001]
  • [Cites] Brain Res. 2016 Aug 1;1644:149-60 [27174003.001]
  • [Cites] J Mol Neurosci. 2017 May;62(1):88-98 [28378260.001]
  • [Cites] JAMA. 2014 Dec 24-31;312(24):2668-75 [25536258.001]
  • [Cites] Circulation. 1999 Sep 7;100(10):1132-3 [10477541.001]
  • [Cites] Ann Intern Med. 2009 May 5;150(9):604-12 [19414839.001]
  • [Cites] J Mol Neurosci. 2008;34(1):77-87 [18040888.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2005 Dec;76 Suppl 5:v2-7 [16291918.001]
  • [Cites] J Am Coll Cardiol. 2017 Jan 24;69(3):345-357 [28104076.001]
  • [Cites] J Alzheimers Dis. 2016 May 3;53(2):393-402 [27163819.001]
  • [Cites] J Am Geriatr Soc. 2012 May;60(5):916-21 [22458300.001]
  • [Cites] J Alzheimers Dis. 2016;51(2):501-14 [26890736.001]
  • [Cites] Lancet. 2015 Jun 6;385(9984):2255-63 [25771249.001]
  • [Cites] Med Care. 2007 Oct;45(10 Supl 2):S103-7 [17909367.001]
  • [Cites] Neuroscience. 2006 Nov 17;143(1):165-73 [16978790.001]
  • [Cites] Arch Intern Med. 1997 Apr 28;157(8):836-48 [9129543.001]
  • [Cites] ACS Chem Neurosci. 2016 Feb 17;7(2):131-42 [26667832.001]
  • [Cites] J Alzheimers Dis. 2011;24(3):485-93 [21297276.001]
  • [Cites] Stat Med. 2009 Nov 10;28(25):3083-107 [19757444.001]
  • [Cites] Lancet Neurol. 2011 Feb;10(2):187-98 [21147038.001]
  • [Cites] J Alzheimers Dis. 2009;17(4):807-15 [19542620.001]
  • [Cites] Biogerontology. 2013 Dec;14(6):641-9 [24249045.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2014 Oct;69(10):1299-305 [24899525.001]
  • [Cites] Diabetes Care. 2014 Aug;37(8):2291-5 [24879835.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12 [19237574.001]
  • [Cites] Endocrine. 2016 Aug;53(2):350-63 [27160819.001]
  • [Cites] J Am Geriatr Soc. 2012 May;60(5):910-5 [22587853.001]
  • [Cites] Diabetol Metab Syndr. 2013 Feb 15;5(1):6 [23415113.001]
  • [Cites] Diabetes Care. 2006 Aug;29(8):1963-72 [16873813.001]
  • [Cites] Ann Neurol. 2015 Aug;78(2):284-94 [25974006.001]
  • [Cites] Can J Diabetes. 2016 Feb;40(1):73-6 [26778684.001]
  • (PMID = 28954880.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypoglycemic Agents; 0 / Sulfonylurea Compounds; 9100L32L2N / Metformin
  •  go-up   go-down






Advertisement